ecrin-mdr-crcClinical2018colorectal cancerColorectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2646378Japan3ECRIN MDRCompletedfalseA multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancerInterventions: Eribulin is administered intravenously at a dose of 1.4mg/m^2/day on Days 1 and 8, repeated every 21 days. Primary outcome(s): Confirmed objective response rate(ORR) by investigators’ assessment Study Design: Single arm Non-randomized2018-03-152646378JPRN-UMIN000031221